Loading the security page…
The series is stated in the current share scale after splits; dividends are not included in the price
Medpace runs clinical trials for small biotech companies — end to end, with its own people.
What distinguishes it from large contractors is that the company does not assemble a project from subcontractors but runs it with one team: medical oversight, laboratories, statistics and regulatory dossier preparation in house. For a small developer that matters more than price — it has no specialists of its own, and one mistake costs it the whole programme.
The backlog says more about the future than current revenue does, and the client base makes results sensitive to the availability of venture capital: when money gets dearer, start-ups pause programmes. Risks: biotech funding, cancelled studies and a shortage of research sites. The company pays no dividend but buys back stock actively.
Based on the last 12 months of reports, through 30 June 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Medpace Holdings, Inc. (MEDP) is a company in the Health care sector; its shares trade on Nasdaq.
The price of Medpace Holdings, Inc. (MEDP) on November 2, 2026 is 652.79 $, +0.12 % on the day. Over 52 weeks the stock traded between 373.00 $ and 677.90 $; the price now sits 92 % of the way up that range. Over the past year the price changed by +19.29 %. The P/E ratio is 36.86, which is above the sector median (24.61). Market capitalization is 18.12 billion $, rank 3 among 10 stocks of the same industry with a known capitalization.
Medpace Holdings, Inc. trades on Nasdaq under the ticker MEDP. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks MEDP has traded between 373.00 $ and 677.90 $. As of 2 November 2026 the price stood 79.90 % of the way from the 52-week low to the high.
Over one year MEDP shares rose 19.29 %; over six months they rose 18.92 %. Volatility over 90 days is 36.89 %. Dividends are not included: this is price change only, as of 2 November 2026.
MEDP trades at a price-to-earnings ratio of 36.9, above the sector median of 24.6. Price to sales is 6.5, above the sector median of 3.6. Price to book is 41.8, above the sector median of 2.5. Calculated from reports for the period ending 30 June 2026.
Medpace Holdings, Inc. reported revenue of 2.8B $ and net income of 492M $ over the last four quarters. Net margin is 17.67 %. Revenue changed by +24.67 % year over year. Earnings per share are 17.02 $. Market capitalisation is 18.1B $.
MEDP has a return on equity of 113.29 %, above the sector median of −40.58 %. Return on assets is 23.89 %, above the sector median of −30.08 %. Operating margin is 20.97 %, above the sector median of −20.96 %.